Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT07749287
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 121 participants
- Sponsor
- Registry
-
NCT07749287
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT07749287. Randomized; double masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2023-01-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke
- Acronym
- NAC - H2S
- Condition
- Ischemic Cerebral Infarction
- Intervention (Drug)
- N Acetyl cysteine 600mg
- Intervention (Drug)
- Normal (0.9%) saline
- Lead sponsor
- Helwan University
Record details
- Record id
cardio:ct-nct07749287- Content hash
5e77fb337204b265bafb4e21b3bc56a1ed9d9a0c6ae14bb4d5db9d79092a0911